Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365213 | 0.97 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL345490 | 0.97 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL505780 | 0.89 | KDM1A (0.48) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL502648 | 0.86 | KDM1A (0.41) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL28157241 | 0.83 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL29710388 | 0.82 | AHR (0.39) | KDM1AKDM1BKCNH2CA1CA2 | |
| SCHEMBL733675 | 0.82 | AHR (0.39) | KDM1AKDM1BKCNH2CA1CA2 | |
| Tetrahydrofuran SCHEMBL28812758 | 0.77 | KDM1A (0.38) | KDM1AKDM1BKCNH2 | |
| Ether SCHEMBL27967823 | 0.77 | HPGD (0.35) | KDM1AKDM1BKCNH2RAB9A | |
| SCHEMBL23539570 | 0.73 | KDM1A (0.48) | KDM1AKDM1BKCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647624-B1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD (CN) | 2016-10-12 | — | — | EP | claimed |
| CN-104387259-B | One is prepared the method for 2,4,5-trifluoro benzene acetic acid | QUZHOU UNIVERSITY (CN) | 2016-05-04 | — | — | CN | claimed |
| US-9187419-B2 | Intermediates of sitagliptin and preparation process thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2015-11-17 | — | — | US | claimed |
| CN-104387259-A | Method for preparing 2,4,5-trifluorophenylacetic acid | UNIV QUZHOU | 2015-03-04 | — | — | CN | claimed |
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD. (CN) | 2013-10-24 | — | — | US | claimed |
| EP-2647624-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | Zhejiang Hisoar Pharmaceutical Co., Ltd (CN) | 2013-10-09 | — | — | EP | claimed |
| CN-116694697-A | Preparation method of sitagliptin phosphate monohydrate | 安庆朗坤药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-108314688-B | A kind of synthetic method of sitagliptin | 安徽海康药业有限责任公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-106966940-B | A kind of preparation method of Sitagliptin phosphate intermediate N arylmethyl -2S- cyano methyl acridine | 新发药业有限公司 | 2019-03-19 | — | — | CN | disclosed |
| CN-105294479-B | A kind of 3R amino replaces the preparation method of butanamide derivatives | 新发药业有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-105061434-B | Preparation method of sitagliptin phosphate | 新发药业有限公司 | 2017-07-21 | — | — | CN | disclosed |
| CN-106966940-A | A kind of preparation method of Sitagliptin phosphate intermediate N arylmethyls 2S cyano methyl acridines | 新发药业有限公司 | 2017-07-21 | — | — | CN | disclosed |
| EP-2647624-B1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD (CN) | 2016-10-12 | — | — | EP | disclosed |
| EP-2647624-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | Zhejiang Hisoar Pharmaceutical Co., Ltd (CN) | 2013-10-09 | — | — | EP | disclosed |
| CN-102378752-A | Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate | DONG A PHARM CO LTD | 2012-03-14 | — | — | CN | disclosed |
| CN-102378751-A | Improved process for preparing dipeptidyl peptidase-IV inhibitors and intermediates | DONG A PHARM CO LTD | 2012-03-14 | — | — | CN | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| EP-2415753-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | KDM1A 2378/4885KDM1B 2369/4885KCNH2 3226/4885 |
| US-20120016125-A1 | METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | KDM1A 2901/4885KDM1B 2768/4885KCNH2 3043/4885 |
| US-20130281695-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | DPP4, DPP9, DPP3 | KDM1A 2163/4885KDM1B 2457/4885KCNH2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.